Antigenic differences between the EG95-related proteins from Echinococcus granulosus G1 and G6 genotypes: Implications for vaccination

Parasite Immunology

Volumn 35, Issue 2, 2013, Pages 99-102

  Alvarez Rojas, C A ^a   Gauci, C G ^a   Lightowlers, M W ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Echinococcus granulosus; EG95; Epitopes; Genotype; Vaccine

Indexed keywords

EG95 1G1; EPITOPE; GENOMIC DNA; RECOMBINANT VACCINE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIGEN BINDING; ARTICLE; DISEASE CONTROL; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG STRUCTURE; ECHINOCOCCOSIS; ECHINOCOCCUS GRANULOSUS; GENOTYPE; HEALTH PROGRAM; IMMUNOREACTIVITY; MOLECULAR CLONING; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; SHEEP; VACCINATION;

ANIMALS; ANTIBODIES, HELMINTH; ANTIGENS, HELMINTH; ECHINOCOCCOSIS; ECHINOCOCCUS GRANULOSUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HELMINTH PROTEINS; PROTOZOAN VACCINES; SHEEP; SHEEP DISEASES; VACCINES, SYNTHETIC;

ECHINOCOCCUS GRANULOSUS; OVIS ARIES;

EID: 84872405168     PISSN: 01419838     EISSN: 13653024     Source Type: Journal    
DOI: 10.1111/pim.12009     Document Type: Article

References (37)

1. Eckert J, Conraths FJ & Tackmann K. Echinococcosis: an emerging or re-emerging zoonosis? Int J Parasitol 2000; 30: 1283-1294.
2. Jenkins DJ, Romig T & Thompson RC. Emergence/re-emergence of Echinococcus spp.-a global update. Int J Parasitol 2005; 35: 1205-1219.
3. Lightowlers MW, Jensen O, Fernandez E, et al. Vaccination trials in Australia and Argentina confirm the effectiveness of the EG95 hydatid vaccine in sheep. Int J Parasitol 1999; 29: 531-534.
4. Lightowlers MW, Lawrence SB, Gauci CG, et al. Vaccination against hydatidosis using a defined recombinant antigen. Parasite Immunol 1996; 18: 457-462.
5. Barnes TS, Hinds LA, Jenkins DJ, et al. Efficacy of the EG95 hydatid vaccine in a macropodid host, the tammar wallaby. Parasitology 2009; 136: 461-468.
6. Heath DD, Jensen O & Lightowlers MW. Progress in control of hydatidosis using vaccination-a review of formulation and delivery of the vaccine and recommendations for practical use in control programmes. Acta Trop 2003; 85: 133-143.
7. Lightowlers MW. Vaccines against cysticercosis and hydatidosis: foundations in taeniid cestode immunology. Parasitol Int 2006; 55(Suppl): S39-S43.
8. McManus DP & Thompson RC. Molecular epidemiology of cystic echinococcosis. Parasitology 2003; 127(Suppl): S37-S51.
9. McManus DP. Molecular discrimination of taeniid cestodes. Parasitol Int 2006; 55(Suppl): S31-S37.
10. Lahmar S, Rebai W, Boufana BS, et al. Cystic echinococcosis in Tunisia: analysis of hydatid cysts that have been surgically removed from patients. Ann Trop Med Parasitol 2009; 103: 593-604.
11. Li T, Ito A, Nakaya K, et al. Species identification of human echinococcosis using histopathology and genotyping in northwestern China. Trans R Soc Trop Med Hyg 2008; 102: 585-590.
12. Sanchez E, Caceres O, Naquira C, et al. Molecular characterization of Echinococcus granulosus from Peru by sequencing of the mitochondrial cytochrome C oxidase subunit 1 gene. Mem Inst Oswaldo Cruz 2010; 105: 806-810.
13. Guarnera EA, Parra A, Kamenetzky L, Garcia G & Gutierrez A. Cystic echinococcosis in Argentina: evolution of metacestode and clinical expression in various Echinococcus granulosus strains. Acta Trop 2004; 92: 153-159.
14. Kamenetzky L, Gutierrez AM, Canova SG, et al. Several strains of Echinococcus granulosus infect livestock and humans in Argentina. Infect Genet Evol 2002; 2: 129-136.
15. Schneider R, Gollackner B, Schindl M, Tucek G & Auer H. Echinococcus canadensis G7 (pig strain): an underestimated cause of cystic echinococcosis in Austria. Am J Trop Med Hyg 2010; 82: 871-874.
16. Manterola C, Benavente F, Melo A, Vial M & Roa JC. Description of Echinococcus granulosus genotypes in human hydatidosis in a region of southern Chile. Parasitol Int 2008; 57: 342-346.
17. Harandi MF, Hobbs RP, Adams PJ, Mobedi I, Morgan-Ryan UM & Thompson RC. Molecular and morphological characterization of Echinococcus granulosus of human and animal origin in Iran. Parasitology 2002; 125: 367-373.
18. Casulli A, Zeyhle E, Brunetti E, et al. Molecular evidence of the camel strain (G6 genotype) of Echinococcus granulosus in humans from Turkana, Kenya. Trans R Soc Trop Med Hyg 2010; 104: 29-32.
19. Bardonnet K, Piarroux R, Dia L, et al. Combined eco-epidemiological and molecular biology approaches to assess Echinococcus granulosus transmission to humans in Mauritania: occurrence of the 'camel' strain and human cystic echinococcosis. Trans R Soc Trop Med Hyg 2002; 96: 383-386.
20. Kedra AH, Swiderski Z, Tkach VV, et al. Genetic analysis of Echinococcus granulosus from humans and pigs in Poland, Slovakia and Ukraine. A multicenter study. Acta Parasitol 1999; 44: 248-254.
21. De la Rue ML, Takano K, Brochado JF, et al. Infection of humans and animals with Echinococcus granulosus (G1 and G3 strains) and E. ortleppi in Southern Brazil. Vet Parasitol 2011; 19: 177 (1-2): 97-103.
22. Alvarez Rojas CA, Gauci CG, Nolan MJ, Harandi MF & Lightowlers MW. Characterization of the eg95 gene family in the G6 genotype of Echinococcus granulosus. Mol Biochem Parasitol 2002; 183: 115-121.
23. McManus DP, Zhang L, Castrodale LJ, Le TH, Pearson M & Blair D. Short report: molecular genetic characterization of an unusually severe case of hydatid disease in Alaska caused by the cervid strain of Echinococcus granulosus. Am J Trop Med Hyg 2002; 67: 296-298.
24. Haag KL, Gottstein B & Ayala FJ. The EG95 antigen of Echinococcus spp. contains positively selected amino acids, which may influence host specificity and vaccine efficacy. PLoS ONE 2009; 4: e5362.
25. Zhang W, Li J, You H, et al. Short report: Echinococcus granulosus from Xinjiang, PR China: cDNAS encoding the EG95 vaccine antigen are expressed in different life cycle stages and are conserved in the oncosphere. Am J Trop Med Hyg 2003; 68: 40-43.
26. Chow C, Gauci CG, Vural G, et al. Echinococcus granulosus: variability of the host-protective EG95 vaccine antigen in G6 and G7 genotypic variants. Exp Parasitol 2008; 119: 499-505.
27. Welch M, Govindarajan S, Ness JE, et al. Design parameters to control synthetic gene expression in Escherichia coli. PLoS ONE 2009; 4: e7002.
28. Gauci C, Jenkins D & Lightowlers MW. Strategies for optimal expression of vaccine antigens from Taeniid cestode parasites in Escherichia coli. Mol Biotechnol 2011; 48: 277-289.
29. Woollard DJ, Gauci CG, Heath DD & Lightowlers MW. Protection against hydatid disease induced with the EG95 vaccine is associated with conformational epitopes. Vaccine 2000; 19: 498-507.
30. Baneyx F. Recombinant protein expression in Escherichia coli. Curr Opin Biotechnol 1999; 10: 411-421.
31. Chow C, Gauci CG, Cowman AF & Lightowlers MW. Echinococcus granulosus: oncosphere-specific transcription of genes encoding a host-protective antigen. Exp Parasitol 2004; 106: 183-186.
32. Chow C, Gauci CG, Cowman AF & Lightowlers MW. A gene family expressing a host-protective antigen of Echinococcus granulosus. Mol Biochem Parasitol 2001; 118: 83-88.
33. Steward A, Adhya S & Clarke J. Sequence conservation in Ig-like domains: the role of highly conserved proline residues in the fibronectin type III superfamily. J Mol Biol 2002; 318: 935-940.
34. Pankov R & Yamada KM. Fibronectin at a glance. J Cell Sci 2002; 115: 3861-3863.
35. Craig D, Gao M, Schulten K & Vogel V. Tuning the mechanical stability of fibronectin type III modules through sequence variations. Structure 2004; 12: 21-30.
36. Vogel V & Sheetz M. Local force and geometry sensing regulate cell functions. Nat Rev Mol Cell Biol 2006; 7: 265-275.
37. Karuri NW, Lin Z, Rye HS & Schwarzbauer JE. Probing the conformation of the fibronectin III1-2 domain by fluorescence resonance energy transfer. J Biol Chem 2009; 284: 3445-3452.